In vitro Diagnosis of Immediate Drug Hypersensitivity: Should We Go with the Flow? | Zendy

Evelyne Mangodt | Zendy; Athina L. Van Gasse | Zendy; Ine I. Decuyper | Zendy; Astrid Uyttebroek | Zendy; Margaretha A. Faber | Zendy; Vito Sabato | Zendy; Chris H. Bridts | Zendy; Margo M. Hagendorens | Zendy; Didier G. Ebo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In vitro Diagnosis of Immediate Drug Hypersensitivity: Should We Go with the Flow?

Author(s) -

Evelyne Mangodt,

Athina L. Van Gasse,

Ine I. Decuyper,

Astrid Uyttebroek,

Margaretha A. Faber,

Vito Sabato,

Chris H. Bridts,

Margo M. Hagendorens,

Didier G. Ebo

Publication year - 2015

Publication title -

international archives of allergy and immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.696

H-Index - 100

eISSN - 1423-0097

pISSN - 1018-2438

DOI - 10.1159/000440663

Subject(s) - basophil activation , medicine , drug allergy , gold standard (test) , provocation test , drug , immunoglobulin e , allergy , immunology , anaphylaxis , diagnostic test , basophil , intensive care medicine , antibody , pharmacology , pathology , pediatrics , alternative medicine

Diagnosis of immediate drug hypersensitivity reactions (IDHRs) is based upon history taking, skin prick or intradermal tests and quantification of specific immunoglobulin E (IgE) antibodies. Unfortunately, this is often insufficient to correctly identify patients with IgE-mediated IDHRs and is impossible in the case of non-IgE-mediated IDHRs. Drug provocation tests (DPT) are considered the 'gold standard' diagnostic but are not always possible, for ethical and practical reasons. Therefore, the validation of new cellular tests such as basophil activation testing (BAT) was necessary. This review focuses on the applications of BAT in IDHRs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research